Early Acute Leukemia Relapse After CD19‐Directed CAR‐T With Lineage Switch From B to T‐ALL in a Pediatric Patient
NB, RA, JG, HM (up to 05/31/2025), and JW are employed by Novartis. IK is the Senior Vice President of Translational Medicine at Adaptive Biotechnologies. RD owns stock in Pfizer.
Authors
- Anant Vatsayan (ORCID: https://orcid.org/0000-0003-2993-0490)
- Reuven J. Schore (ORCID: https://orcid.org/0000-0002-1582-2168)
- Sam Sirotnikov
- Yannan J. Wang
- R A Dul'man
- Jingbo Gao
- Rakesh Awasthi
- Ilan Kirsch
- Jennifer Willert
- Hans Menssen
- Keri Toner
- Nefeli Beri
Institutions
- Novartis (Switzerland) (CH)
- Children's National (US)
- George Washington University (US)
- Adaptive Biotechnologies (United States) (US)
- Center for Cancer and Blood Disorders (US)
- Virginia Cancer Specialists (US)
- Tris Pharma (United States) (US)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2026-07-25
- DOI
- https://doi.org/10.1002/1545-5017.70538
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00